Baseline and followup medication exposures.
| Baseline medication exposures1 | |
| Methotrexate | 7694 (32.1) |
| Other DMARD | 8562 (35.7) |
| Glucocorticosteroids | 13,758 (57.3) |
| COXIB | 9725 (40.5) |
| NSAID | 8963 (37.4) |
| Antihypertensive agents | 15,247 (63.5) |
| Statins | 9334 (38.9) |
| Followup medication exposures2 | |
| Methotrexate | 11,896 (49.6) |
| Other DMARD | 12,875 (53.7) |
| Glucocorticosteroids | 16,247 (67.7) |
| COXIB | 10,065 (41.9) |
| NSAID | 8491 (35.4) |
| Anti-TNF | 1015 (4.2) |
| Other bDMARD | 192 (0.8) |
| Antihypertensive agents | 18,543 (77.3) |
| Statins | 11,868 (49.5) |
Data are n (%).
↵1 Ascertained over the 1 year prior to cohort entry.
↵2 Proportion of patients with at least 1 prescription during followup. DMARD: disease-modifying antirheumatic drugs; bDMARD: biologic DMARD; COXIB: cyclooxygenase-2 inhibitors; NSAID: nonsteroidal antiinflammatory drug; TNF: tumor necrosis factor.